

Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects

Supplemental Information

Table S1. Studies of Immune Cell Parameters in Schizophrenia

Study	Cell Subsets	Method	Antipsychotic	Location	Included	Patient Group(s)/Comment
Achiron 1994 (17)	Lymphocytes, CD4%, CD8%	Flow cytometry	No	Israel	Yes	AR
Arolt 1997 (18)	WBC, Lymphocytes, Monocytes, CD3%, CD4% CD8%, CD19%	Flow cytometry	No	Germany	No	Clinical status not available
Baskak 2008 (19)	CD3%, CD4%, CD8%, CD4/CD8	Flow cytometry	No	Turkey	Yes	FEP; Treatment
Billici 2003 (20)	CD3%, CD4%, CD8%, CD4/CD8, CD19%	Flow cytometry	Yes	Turkey	Yes	Treatment
Carlton 2009 (21)	Monocytes	Impedance cell counter	No	U.S.	Yes	FEP
Cazzullo 1998 (22)	CD3, CD4, CD8, CD4/CD8, CD19	Flow cytometry	No	Italy	No	Mean/SD not given
Chang 2011 (23)	WBC, Lymphocytes	Impedance cell counter	Unknown	Taiwan	No	Clinical status not available
Coffey 1983 (24)	Lymphocytes	Impedance cell counter	Yes/No	U.S.	Yes	AR
Cosentino 1996 (25)	Lymphocytes, CD3%, CD4%, CD8%, CD4/CD8, CD56%	Flow cytometry	Yes	Italy	No	Stratified data not available
Craddock 2007 (26)	CD4, CD8	Flow cytometry	Yes/No	U.K.	No	Clinical status not available
DeLisi 1982 (27)	CD3%, CD4%, CD8%, CD56%	Flow cytometry	Yes/No	U.S.	No	Chronic inpatients
Dimitrov 2011 (28)	Monocytes	Impedance cell counter	Yes	U.S.	No	No control group
Dvorakova 1979 (29)	CD3%, CD19%	Rosette formation	Unknown	Czech Repub	No	Clinical status not available
Ferguson 1978 (30)	CD3	Rosette formation	Yes/No	U.S.	No	Clinical status not available
Ganguli 1987 (31)	CD4, CD8	Flow cytometry	Yes	U.S.	No	Mean/SD not given
Ganguli 1993 (32)	CD5, CD5%	Flow cytometry	Yes/No	U.S.	Yes	AR/FEP
Henneberg 1990 (33)	CD4%, CD8%, CD4/CD8	Fluorescence microscopy	Yes/No	Germany	Yes	AR
Hornberg 1995 (34)	WBC, CD4/CD8	Flow cytometry	Yes	Germany	No	Mean/SD not given
Kaufman 1987 (35)	CD4/CD8	Fluorescence microscopy	Yes/No	U.S.	No	Mean/SD not given
Kolyaskina 1983 (36)	CD3	Rosette formation	Unknown	Russia	No	Mean/SD not given
Kolyaskina 1987 (37)	CD*	Rosette formation	Unknown	Russia	No	Mean/SD not given
Maino 2007 (38)	CD3%, CD19%	Flow cytometry	No	Germany	No	AR; Treatment
Masserini 1990 (39)	Lymphocytes, CD3, CD3%, CD4, CD4%, CD8 CD8%, CD19, CD19%	Microscopy	Yes/No	Italy	Yes	FEP
Mazzarello 2004 (40)	CD4, CD4%, CD8%, CD19%	Flow cytometry	Yes	Italy	No	Mean/SD not given
McAllister 1989 (41)	CD3%, CD4%, CD8%, CD4/CD8, CD19%	Flow cytometry	Yes	U.S.	No	Clinical status not available
Muller 1991 (42)	CD3, CD3%, CD4, CD4%, CD8, CD8%, CD4/CD8	Immunofluorescence assay	Yes/No	Germany	Yes	AR; Treatment
Muller 1993 (43)	CD3, CD4, CD8	Immunofluorescence assay	Yes/No	Germany	No	Population overlap (Muller 1991)
Muller 1998 (44)	CD8 gamma/delta	Flow cytometry	No	Germany	No	Clinical status not available
Nikkila 1995 (45)	CSF CD4, CD8, CD4/CD8	Light microscopy	Yes	Finland	No	CSF
Nikkila 1999 (46)	CSF Monocytes	Light microscopy	Yes	Finland	No	CSF
Nikkila 2001 (47)	CSF Lymphocytes, Monocytes	Light microscopy	Yes	Finland	No	CSF
Nyland 1980 (48)	Lymphocytes, CD3, CD3%, CD19, CD19%	Rosette formation	Yes	Norway	Yes	AR; SO
Printz 1999 (49)	CD3, CD3%, CD4%, CD5, CD5%, CD8%, CD4/CD8, CD19, CD19%	Flow cytometry	Yes/No	U.S.	No	Clinical status not available
Rabin 1988 (50)	Lymphocytes, CD4%, CD8%, CD4/CD8	Not specified	Unknown	U.S.	No	Clinical status not available
Rothermundt 1998 (51)	WBC, Lymphocytes, Monocytes, CD3, CD19	Flow cytometry	No	Germany	No	No control group
Rudolf 2004 (52)	CD3, CD3%, CD4, CD4%, CD8, CD8%, CD4/CD8 CD19, CD19%, CD25%, CD56, CD56%	Flow cytometry	Yes/No	Germany	Yes	AR
Sasaki 1994 (53)	WBC, Lymphocytes, CD3%, CD4%, CD8%, CD4/CD8, CD25%, CD56%	Flow cytometry	Yes	Japan	Yes	AR; Treatment
Schattner 1996 (54)	CD4, CD8, CD4/CD8	Flow cytometry	Unknown	Israel	No	Stratified data not available
Schleifer 1985 (55)	Lymphocytes, CD3, CD3%, CD19, CD19%	Rosette formation	Unknown	U.S.	No	Stratified data not available
Sperner-Unterweger 1999 (56)	WBC, Lymphocytes, CD3, CD4, CD8, CD4/CD8, CD56	Flow cytometry	Yes/No	Austria	Yes	AR; FEP; Treatment
Steiner 2010 (16)	CD3, CD4, CD8, CD4/CD8, CD19, CD56	Flow cytometry	Yes/No	Germany	Yes	AR; Treatment
Theodoropoulou 2001 (57)	CD3%, CD4%, CD8%, CD4/CD8, CD19%, CD25%	Flow cytometry	Yes/No	Greece	Yes	FEP; SO
Torres 2009 (58)	Monocytes, CD4, CD19, CD56	Flow cytometry	Yes	Brazil	No	Clinical status not available
Vartanian 1978 (59)	CD3%	Rosette formation	Unknown	Russia	No	Clinical status not available

Study	Cell Subsets	Method	Antipsychotic	Location	Included	Patient Group(s)/Comment
Villemain 1989 (60)	CD4%, CD8%, CD4/CD8	Rosette formation	No	France	No	Clinical status not available
Wahlbeck 2000 (61)	CSF Monocytes	Light microscopy	Yes	Finland	No	No control group
Wilke 1996 (62)	WBC, Monocytes	Flow cytometry	Yes	Germany	No	Stratified data not available
Zarrabi 1979 (63)	CD3%, CD19%	Rosette formation	Yes	U.S.	No	Mean/SD not given
Zorrilla 1996 (64)	WBC, Lymphocytes, Monocytes	Impedance cell counter	Yes/No	U.S.	No	Clinical status not available
Zorrilla 1998 (65)	Lymphocytes	Impedance cell counter	Yes	U.S.	No	Mean/SD not given

All reference numbers refer to those in the main text. See main text for full reference details.

Studies that were included are indicated by **bold** font.

AR, acutely relapsed inpatients; CSF, cerebrospinal fluid; FEP, first-episode psychosis; SO, stable medicated outpatients; WBC, white blood cell.




Figure S1. Flow chart of the study selection process. CSF, cerebrospinal fluid.

Table S2. Effect size estimates for individual immune parameters

Study	Schizophrenia			Control			Hedges <i>g</i>	95% CI		Subset	Notes	Clinical Status
	Mean	N	SD	Mean	N	SD		Lower	Upper			
Achiron 1994	33.5	16	9.0	38.6	16	11.9	-0.47	-1.17	0.23	CD4%	Blood	AR
Achiron 1994	28.8	16	15.3	24.5	16	6.1	0.36	-0.34	1.06	CD8%	Blood	AR
Achiron 1994	2167	16	1054	1034	16	8980	0.17	-0.52	0.87	Lymphs	Blood	AR
Coffey 1983	2689	33	1086	2119	15	995	0.53	-0.09	1.15	Lymphs	Blood	AR
Ganguli 1993	207	29	155	176	166	129	0.23	-0.17	0.62	CD19	Blood	AR
Henneberg 1990	1.80	30	1.10	1.80	30	0.70	0.00	-0.51	0.51	CD4/CD8	Blood	AR
Henneberg 1990	40.3	30	13.5	33.8	30	8.6	0.57	0.05	1.08	CD4%	Blood	AR
Henneberg 1990	28.9	30	18.5	21.6	30	8.6	0.50	-0.01	1.01	CD8%	Blood	AR
Maino 2007	12.4	40	4.4	10.5	20	2.9	0.47	-0.07	1.02	CD19%	Blood	AR
Maino 2007	66.3	40	8.0	70.7	20	5.1	-0.60	-1.15	-0.06	CD3%	Blood	AR
Muller 1991	1324	51	551	1016	38	457	0.59	0.17	1.02	CD3	Blood	AR
Muller 1991	54.0	51	11.0	45.0	38	12.0	0.78	0.34	1.22	CD3%	Blood	AR
Muller 1991	882	51	409	697	38	312	0.49	0.07	0.92	CD4	Blood	AR
Muller 1991	1.83	51	0.77	1.52	38	0.62	0.43	0.01	0.86	CD4/CD8	Blood	AR
Muller 1991	36.0	51	10.0	31.0	38	9.0	0.52	0.09	0.94	CD4%	Blood	AR
Muller 1991	498	51	218	517	38	248	-0.08	-0.50	0.34	CD8	Blood	AR
Muller 1991	21.0	51	6.0	22.0	38	7.0	-0.15	-0.57	0.27	CD8%	Blood	AR
Nyland 1980	598	12	319	580	30	246	0.07	-0.60	0.74	CD19	Blood	AR
Nyland 1980	25.0	12	13.9	26.0	30	11.0	-0.08	-0.75	0.59	CD19%	Blood	AR
Nyland 1980	1238	27	462	1538	30	860	-0.42	-0.95	0.10	CD3	Blood	AR
Nyland 1980	60.0	27	10.4	66.0	30	5.5	-0.72	-1.26	-0.19	CD3%	Blood	AR
Nyland 1980	2079	27	675	2330	30	707	-0.36	-0.88	0.17	Lymphs	Blood	AR
Rudolf 2004	208	31	85	228	31	81	-0.24	-0.74	0.26	CD19	Blood	AR
Rudolf 2004	12.5	31	4.8	14.1	31	4.3	-0.35	-0.85	0.15	CD19%	Blood	AR
Rudolf 2004	9.4	31	3.9	10.6	31	3.9	-0.30	-0.80	0.20	CD25%	Blood	AR
Rudolf 2004	1207	31	325	1214	31	294	-0.02	-0.52	0.48	CD3	Blood	AR
Rudolf 2004	72.1	31	7.4	73.5	31	5.1	-0.22	-0.72	0.28	CD3%	Blood	AR
Rudolf 2004	770	31	245	809	31	263	-0.15	-0.65	0.35	CD4	Blood	AR
Rudolf 2004	2.80	31	1.90	2.40	31	1.80	0.21	-0.29	0.71	CD4/CD8	Blood	AR
Rudolf 2004	47.6	31	9.5	48.8	31	8.7	-0.13	-0.63	0.37	CD4%	Blood	AR
Rudolf 2004	215	31	137	156	31	73	0.53	0.02	1.04	CD56	Blood	AR
Rudolf 2004	12.1	31	6.5	9.4	31	3.3	0.52	0.01	1.02	CD56%	Blood	AR
Rudolf 2004	361	31	152	352	31	116	0.07	-0.43	0.56	CD8	Blood	AR
Rudolf 2004	21.5	31	8.4	21.5	31	5.7	0.00	-0.50	0.50	CD8%	Blood	AR
Rudolf 2004	1682	31	419	1650	31	369	0.08	-0.42	0.58	Lymphs	Blood	AR
Sasaki 1994	2.5	14	3.0	1.5	20	1.5	0.44	-0.25	1.13	CD25%	Blood	AR
Sasaki 1994	70.9	14	7.4	73.9	20	5.9	-0.45	-1.14	0.24	CD3%	Blood	AR
Sasaki 1994	1.79	14	0.70	1.52	20	0.41	0.48	-0.21	1.17	CD4/CD8	Blood	AR
Sasaki 1994	44.5	14	6.4	41.6	20	5.7	0.47	-0.22	1.16	CD4%	Blood	AR
Sasaki 1994	13.3	14	5.4	6.7	20	2.9	1.57	0.79	2.35	CD56%	Blood	AR
Sasaki 1994	27.1	14	6.6	28.6	20	5.2	-0.25	-0.94	0.43	CD8%	Blood	AR
Sasaki 1994	1759	14	416	2152	20	497	-0.82	-1.53	-0.11	Lymphs	Blood	AR
Sasaki 1994	6.2	14	1.5	5.8	20	1.1	0.33	-0.36	1.02	WBC	Blood	AR
Sperner-Unterweger 1999	1585	34	577	1496	16	514	0.16	-0.44	0.75	CD3	Blood	AR
Sperner-Unterweger 1999	1067	34	432	888	16	288	0.45	-0.15	1.05	CD4	Blood	AR
Sperner-Unterweger 1999	2.34	34	1.42	1.69	16	0.71	0.51	-0.09	1.12	CD4/CD8	Blood	AR
Sperner-Unterweger 1999	224	34	139	352	16	204	-0.78	-1.39	-0.16	CD56	Blood	AR
Sperner-Unterweger 1999	520	34	249	595	16	280	-0.28	-0.88	0.31	CD8	Blood	AR
Sperner-Unterweger 1999	2148	34	681	2121	16	649	0.04	-0.55	0.63	Lymphs	Blood	AR
Sperner-Unterweger 1999	7.8	34	1.9	6.5	16	1.7	0.70	0.09	1.31	WBC	Blood	AR
Steiner 2010	300	26	238	195	32	109	0.58	0.05	1.11	CD19	Blood	AR
Steiner 2010	1211	26	503	1396	32	532	-0.35	-0.87	0.17	CD3	Blood	AR
Steiner 2010	710	26	295	973	32	396	-0.73	-1.27	-0.20	CD4	Blood	AR
Steiner 2010	1.03	26	0.60	1.45	32	0.56	-0.72	-1.25	-0.18	CD4/CD8	Blood	AR
Steiner 2010	540	26	221	396	32	170	0.73	0.20	1.26	CD56	Blood	AR
Steiner 2010	332	26	199	410	32	177	-0.41	-0.93	0.11	CD8	Blood	AR
Baskak 2008	69.4	11	5.9	72.8	14	6.2	-0.54	-1.35	0.26	CD3%	Blood	FEP
Baskak 2008	1.60	11	0.40	1.40	14	0.30	0.56	-0.25	1.36	CD4/CD8	Blood	FEP
Baskak 2008	41.7	11	7.1	41.8	14	6.8	-0.01	-0.80	0.78	CD4%	Blood	FEP
Baskak 2008	25.8	11	5.1	30.9	14	6.8	-0.81	-1.63	0.01	CD8%	Blood	FEP
Ganguli 1993	195	23	135	176	166	129	0.14	-0.29	0.58	CD19	Blood	FEP

Table S2. (continued)

Study	Schizophrenia			Control			Hedges <i>g</i>	95% CI		Subset	Notes	Clinical Status
	Mean	N	SD	Mean	N	SD		Lower	Upper			
Masserini 1990	368	7	116	268	37	112	0.87	0.04	1.70	CD19	Blood	FEP
Masserini 1990	1587	7	696	1214	37	406	0.80	-0.03	1.62	CD3	Blood	FEP
Masserini 1990	69.0	7	10.0	64.0	37	9.0	0.54	-0.28	1.35	CD3%	Blood	FEP
Masserini 1990	1200	7	432	833	37	274	1.19	0.35	2.04	CD4	Blood	FEP
Masserini 1990	44.0	7	9.0	43.0	37	6.0	0.15	-0.66	0.96	CD4%	Blood	FEP
Masserini 1990	867	7	351	649	37	208	0.91	0.08	1.74	CD8	Blood	FEP
Masserini 1990	38.0	7	8.0	31.0	37	6.0	1.08	0.25	1.92	CD8%	Blood	FEP
Masserini 1990	2251	7	717	1958	37	62	1.04	0.20	1.87	Lymphs	Blood	FEP
Sperner-Unterweger 1999	1967	21	784	1496	16	514	0.68	0.01	1.34	CD3	Blood	FEP
Sperner-Unterweger 1999	1165	21	496	888	16	288	0.65	-0.02	1.31	CD4	Blood	FEP
Sperner-Unterweger 1999	2.27	21	1.21	1.69	16	0.71	0.55	-0.11	1.22	CD4/CD8	Blood	FEP
Sperner-Unterweger 1999	649	21	421	595	16	280	0.14	-0.51	0.79	CD8	Blood	FEP
Sperner-Unterweger 1999	2736	21	1216	2121	16	649	0.59	-0.07	1.26	Lymphs	Blood	FEP
Theodoropoulou 2001	64.0	53	6.0	68.0	60	11.0	-0.44	-0.81	-0.07	CD3%	Blood	FEP
Theodoropoulou 2001	40.0	52	8.0	40.0	60	8.0	0.00	-0.37	0.37	CD4%	Blood	FEP
Theodoropoulou 2001	26.0	52	16.0	27.0	60	7.0	-0.08	-0.45	0.29	CD8%	Blood	FEP
Nyland 1980	67.0	10	9.5	66.0	30	5.5	0.15	-0.57	0.86	CD3%	Blood	SO
Theodoropoulou 2001	61.0	29	11.0	68.0	60	11.0	-0.63	-1.08	-0.18	CD3%	Blood	SO
Study	Pre-Treatment			Post-Treatment			Hedges <i>g</i>	95% CI		Subset	Notes	Clinical Status
	Mean	N	SD	Mean	N	SD		Lower	Upper			
Billici 2003	11.9	20	2.7	12.1	20	1.1	-0.09	-0.71	0.53	CD19%	Treatment	AR
Maino 2007	12.4	40	4.4	9.6	11	3.4	0.65	-0.03	1.33	CD19%	Treatment	AR
Muller 1991	1324	51	551	1523	26	636	-0.34	-0.81	0.14	CD3	Treatment	AR
Sperner-Unterweger 1999	1585	34	577	1662	16	647	-0.13	-0.72	0.47	CD3	Treatment	AR
Steiner 2010	1063	11	612	1425	11	608	-0.56	-1.42	0.29	CD3	Treatment	AR
Billici 2003	65.1	20	7.4	61.8	20	3.4	0.57	-0.06	1.20	CD3%	Treatment	AR
Maino 2007	66.3	40	8.0	67.8	11	6.9	-0.19	-0.86	0.48	CD3%	Treatment	AR
Muller 1991	54.0	51	11.0	58.0	26	9.0	-0.38	-0.86	0.09	CD3%	Treatment	AR
Sasaki 1994	70.9	14	7.4	75.6	14	6.3	-0.66	-1.42	0.10	CD3%	Treatment	AR
Muller 1991	882	51	409	1012	26	448	-0.30	-0.78	0.17	CD4	Treatment	AR
Sperner-Unterweger 1999	1067	34	432	1122	16	447	-0.13	-0.72	0.47	CD4	Treatment	AR
Steiner 2010	621	11	358	956	11	392	-0.85	-1.72	0.03	CD4	Treatment	AR
Billici 2003	1.36	20	0.22	1.20	20	0.10	0.92	0.27	1.57	CD4/CD8	Treatment	AR
Muller 1991	1.83	51	0.77	1.83	32	0.89	0.00	-0.44	0.44	CD4/CD8	Treatment	AR
Sasaki 1994	1.79	14	0.70	1.54	14	0.39	0.43	-0.32	1.18	CD4/CD8	Treatment	AR
Sperner-Unterweger 1999	2.34	34	1.42	2.32	16	1.39	0.01	-0.58	0.61	CD4/CD8	Treatment	AR
Billici 2003	34.7	20	4.8	35.7	20	3.2	-0.24	-0.86	0.38	CD4%	Treatment	AR
Muller 1991	36.0	51	10.0	39.0	26	9.0	-0.31	-0.78	0.17	CD4%	Treatment	AR
Sasaki 1994	44.5	14	6.4	43.7	14	6.3	0.12	-0.62	0.86	CD4%	Treatment	AR
Sperner-Unterweger 1999	224	34	139	380	16	187	-0.99	-1.61	-0.36	CD56	Treatment	AR
Steiner 2010	461	11	261	496	11	314	-0.12	-0.95	0.72	CD56	Treatment	AR
Billici 2003	11.2	20	2.8	12.3	20	1.7	-0.48	-1.11	0.15	CD56%	Treatment	AR
Sasaki 1994	13.3	14	5.4	10.7	14	4.3	0.52	-0.24	1.27	CD56%	Treatment	AR
Muller 1991	498	51	218	637	26	313	-0.54	-1.02	-0.06	CD8	Treatment	AR
Sperner-Unterweger 1999	520	34	249	557	16	291	-0.14	-0.73	0.46	CD8	Treatment	AR
Steiner 2010	280	11	254	492	11	259	-0.78	-1.65	0.08	CD8	Treatment	AR
Billici 2003	25.4	20	5.6	29.6	20	4.4	-0.82	-1.46	-0.17	CD8%	Treatment	AR
Muller 1991	21.0	51	6.0	24.0	26	7.0	-0.47	-0.95	0.01	CD8%	Treatment	AR
Sasaki 1994	27.1	14	6.6	28.1	14	4.3	-0.17	-0.92	0.57	CD8%	Treatment	AR
Sasaki 1994	1759	14	416	1473	14	265	0.79	0.02	1.56	Lymphs	Treatment	AR
Sperner-Unterweger 1999	2148	34	681	2290	16	762	-0.20	-0.79	0.40	Lymphs	Treatment	AR
Sasaki 1994	6.2	14	1.5	5.3	14	1.1	0.67	-0.09	1.44	WBC	Treatment	AR
Sperner-Unterweger 1999	7.8	34	1.9	7.7	16	2.6	0.06	-0.54	0.65	WBC	Treatment	AR

Table S2. (continued)

Study	Pre-Treatment			Post-Treatment			Hedges <i>g</i>	95% CI		Subset	Notes	Clinical Status
	Mean	N	SD	Mean	N	SD		Lower	Upper			
Sperner-Unterweger 1999	1967	21	784	1614	16	375	0.54	-0.12	1.20	CD3	Treatment	FEP
Baskak 2008	70.6	10	6.4	75.9	10	3.5	-0.98	-1.90	-0.05	CD3%	Treatment	FEP
Sperner-Unterweger 1999	1165	21	496	1008	16	254	0.38	-0.28	1.03	CD4	Treatment	FEP
Baskak 2008	1.60	10	0.50	1.50	10	0.50	0.19	-0.69	1.07	CD4/CD8	Treatment	FEP
Sperner-Unterweger 1999	2.27	21	1.21	1.88	16	0.78	0.36	-0.29	1.02	CD4/CD8	Treatment	FEP
Baskak 2008	42.7	10	8.5	43.8	10	7.4	-0.13	-1.01	0.75	CD4%	Treatment	FEP
Sperner-Unterweger 1999	327	21	224	447	16	354	-0.41	-1.07	0.25	CD56	Treatment	FEP
Sperner-Unterweger 1999	649	21	421	632	16	326	0.04	-0.61	0.69	CD8	Treatment	FEP
Baskak 2008	26.5	10	5.6	30.7	10	6.1	-0.68	-1.58	0.22	CD8%	Treatment	FEP
Sperner-Unterweger 1999	2736	21	1216	2163	16	529	0.57	-0.09	1.23	Lymphs	Treatment	FEP
Sperner-Unterweger 1999	8.1	21	2.1	7.2	16	1.9	0.42	-0.23	1.08	WBC	Treatment	FEP

AR, acutely relapsed inpatients; EP, first-episode psychosis; SO, stable medicated outpatients; WBC, white blood cell.

Following Antipsychotic Treatment for Acute Exacerbation of Psychosis

Parameter	Studies	N		Mean	Mean ES	95% CI	p-value	Heterogeneity		I ²	References	
		Pt	Control	Duration (weeks)				χ ²	p-value			
WBC	3	69	46	3	-0.34	-0.72	0.05	0.09	1.67	0.43	0.0	53, 56
Lymphocytes	3	69	46	3	-0.31	-0.69	0.08	0.12	4.89	0.09	59.1	53, 56
CD3	4	117	69	7	0.13	-0.17	0.43	0.41	5.65	0.13	46.9	16, 42, 56
CD3%	5	135	81	11	0.25	-0.04	0.53	0.10	10.30	0.04	61.2	19, 20, 38, 42, 53
CD4	4	117	69	7	0.18	-0.12	0.48	0.25	5.31	0.15	43.5	16, 42, 56
CD4%	4	95	70	11	0.19	-0.12	0.51	0.23	0.96	0.81	0.0	19, 20, 42, 53
CD8	4	117	69	7	0.34	0.04	0.64	0.03	3.46	0.33	13.3	16, 42, 56
CD8%	4	95	70	11	0.53	0.21	0.85	<0.01	1.82	0.61	0.0	19, 20, 42, 53
CD4/CD8	6	150	108	8	-0.26	-0.51	-0.01	0.05	6.21	0.29	19.5	19, 20, 42, 53, 56
CD19												
CD19%	2	60	31	12	0.25	-0.21	0.70	0.29	2.55	0.11	60.7	20, 38
CD25%												
CD56	3	66	43	3	0.58	0.18	0.98	<0.01	3.07	0.22	34.9	16, 56
CD56%	2	34	34	10	-0.07	-0.55	0.41	0.78	3.95	0.05	74.7	20, 53

All reference numbers refer to those in the main text. See main text for full reference details.
 CI, confidence interval; ES, effect size; Pt, patient; WBC, white blood cell.